MAM
ACHN

Meeder Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Meeder Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,551
Closed -$70K – 2526
2019
Q3 		$70K Buy
19,551
+17,035
+677% +$65.7K ﹤0.01% 906
2019
Q2 		$7K Sell
2,516
-1,069
-30% -$3.16K ﹤0.01% 1590
2019
Q1 		$11K Sell
3,585
-22,891
-86% -$56.2K ﹤0.01% 1230
2018
Q4 		$42K Buy
26,476
+13,706
+107% +$38.7K ﹤0.01% 861
2018
Q3 		$46K Buy
12,770
+11,507
+911% +$34.3K ﹤0.01% 806
2018
Q2 		$3.57K Hold
1,263
– – ﹤0.01% 1329
2018
Q1 		$5K Buy
1,263
+116
+10% +$380 ﹤0.01% 1258
2017
Q4 		$3K Buy
1,147
+213
+23% +$774 ﹤0.01% 1462
2017
Q3 		$4K Sell
934
-994
-52% -$4.41K ﹤0.01% 1348
2017
Q2 		$9K Sell
1,928
-147
-7% -$591 ﹤0.01% 1035
2017
Q1 		$9K Hold
2,075
– – ﹤0.01% 894
2016
Q4 		$9K Buy
+2,075
New +$11K ﹤0.01% 783

Other funds holding ACHN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's ACHN Position: Q4 2019 in Review

Meeder Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2019, closing a stake of 19,551 shares — an estimated $70K sold.

Meeder Asset Management first reported a position in ACHN in Q4 2016 and held it in 12 quarters. The position peaked at $70K in Q3 2019. 132 funds tracked by Wall St. Rank hold ACHN as of Q4 2019.

  • Meeder Asset Management reported no remaining Achillion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Meeder Asset Management sold 19,551 Achillion Pharmaceuticals shares in Q4 2019, an estimated $70K.
  • Meeder Asset Management first reported a position in Achillion Pharmaceuticals in Q4 2016 and held it in 12 quarters.
  • Meeder Asset Management's Achillion Pharmaceuticals position peaked at $70K in Q3 2019.
  • 132 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2019.

Based on Meeder Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.